OBJECTIVE： To observe the preventive effects and safety of 3 kinds of drugs on chemotherapy-induced liver damage in patients with  gastrointestinal tumors， and to evaluate economics. METHODS： A total of 128 patients with gastrointestinal malignant tumor and systemic chemotherapy indication selected from our hospital during 2014-2015 were divided into group A （42 cases）， B （46 cases） and C （40 cases） according to random number table. Since the first day of chemotherapy， group A， B and C were given Reduced glutathione for injection （1.2 g）， Magnesium isoglycyrrhizinate injection （100 mg） and Polyene phosphatidylcholine injection （465 mg） for preventing chemotherapy-induced liver damage respectively， for 7 d. The preventive effects and ADR occurrence were observed in 3 groups， and the economic analysis was conducted. RESULTS： Total response rates of group A， B and C were 90.48％， 97.83％ and 87.50％， and that of group B was significantly higher than other 2 groups， with statistical significance （P＜0.05）. But there was no statistical significance between group A and C （P＞0.05）. The costs of group A， B and C were 1 465.86， 1 518.94， 1 554.04 yuan， and cost-minimization analysis was adopted to evaluate the plans of group A and C. The plan of group A was more economical. Cost-effectiveness analysis was used to evaluate the plans of group A and B， cost-effectiveness ratio of group A and B were 1 620.09 and 1 552.63； incremental cost-effectiveness ratio was 722.18， and the plan of group B was more economical. The above conclusion was supported by the results of sensitivity analysis. Three patients in group B suffered from transient elevated blood pressure and then recovered 2-3 d after drug withdrawal. CONCLUSIONS： The preventive effects and economics of Magnesium isoglycyrrhizinate injection is better than Reduced glutathione for injection and Polyene phosphatidylcholine injection for chemotherapy-induced liver damage in patients with gastrointestinal tumors. The blood pressure of patients should be monitored closely during application. Reduced glutathione for injection is more suitable for patients with primary hypertensive disease.